Goel, Shom
DeCristo, Molly J.
Watt, April C.
BrinJones, Haley
Sceneay, Jaclyn
Li, Ben B.
Khan, Naveed
Ubellacker, Jessalyn M.
Xie, Shaozhen
Metzger-Filho, Otto
Hoog, Jeremy
Ellis, Matthew J.
Ma, Cynthia X.
Ramm, Susanne
Krop, Ian E.
Winer, Eric P.
Roberts, Thomas M.
Kim, Hye-Jung
McAllister, Sandra S.
Zhao, Jean J.
Article History
Received: 7 December 2016
Accepted: 3 July 2017
First Online: 16 August 2017
Competing interests
: S.G. has served as a paid scientific adviser to Eli Lilly, and conducts laboratory research funded by Eli Lilly. Eli Lilly did not fund the present study. M.J.E. has performed ad hoc consulting for Novartis, Pfizer, and AstraZeneca, receives royalties for PAM50-based diagnostics including Prosigna, and holds stock in Bioclassifier LLC for PAM50-based diagnostics. C.X.M. receives research funding from Pfizer and has served as a paid scientific adviser to Pfizer and Novartis.